Hjem › Autoimmune sykdommer › North Carolina › Durham
Kliniske studier for Autoimmune sykdommer i Durham, NC
15 studier for Autoimmune sykdommer søker deltakere på steder i og rundt Durham (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Environmental Risk Factors for the Anti-synthetase Syndrome
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- NIEHS Clinical Research Unit (CRU), Research Triangle Park · 7 mi unna
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RekruttererFase 3
- Duke University Hospital, Durham
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
RekruttererFase 2/3
- Duke University Medical Center - Accepting Young Adults and Juvenile Patients, Durham
- University of North Carolina at Chapel Hill - Accepting Adult Patients, Chapel Hill · 10 mi unna
Daratumumab in Primary Antiphospholipid Syndrome
RekruttererFase 1/2
- Duke University, Durham
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
RekruttererFase 1
- Duke University Medical Center, Durham
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RekruttererFase 3
- Duke University Hospital, Durham
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
RekruttererFase 3
- GSK Investigational Site, Durham
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
RekruttererFase 1/2
- UNC Chapel Hill, Chapel Hill · 10 mi unna
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RekruttererFase 2/3
- Duke University, Durham
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
RekruttererFase 3
- Duke University Medical Center, Durham
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
RekruttererFase 3
- Site Number - 1013, Durham
- Site Number - 1020, Chapel Hill · 10 mi unna
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
RekruttererFase 1
- Duke University, Durham
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RekruttererObservasjonsstudie
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi unna
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
RekruttererFase 1
- Duke University Health System, Durham
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Duke University, Durham
Autoimmune sykdommer-studier i andre byer
- Houston, TX21 studier
- Washington, DC19 studier
- New York City, NY19 studier
- Philadelphia, PA16 studier
- Boston, MA13 studier
- Los Angeles, CA12 studier
- Chicago, IL12 studier
- Dallas, TX9 studier
- Cleveland, OH8 studier
- Atlanta, GA8 studier
- Milwaukee, WI8 studier
- Portland, OR8 studier
Andre studier i Durham
- Brystkreft63 studier
- Kreft (alle typer)58 studier
- Ikke-småcellet lungekreft39 studier
- Multipelt myelom37 studier
- Metastatisk kreft33 studier
- Akut myelogen leukemi33 studier
- Lungekreft32 studier
- Prostatakreft32 studier
- Kolorektal kreft28 studier
- Kronisk lymfatisk leukemi27 studier
- Eggstokkreft27 studier
- Hjertesvikt26 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.